TCL Archive Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent January 8, 1982
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief: Cancer Control To Push Environmental Research Occupational Hazards; Bailer to Journal Post May 24, 1974
